What Barinthus Biotherapeutics does

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom and listed on NASDAQ under ticker BRNS, developing antigen-specific immunotherapies that guide T cells to treat infectious diseases, autoimmune/inflammatory disorders, and cancer. The company was formed in 2021 through the merger of Oxford University spinout Vaccitech plc and NIH/Johns Hopkins University spinout Avidea Technologies, combining two complementary technology platforms: viral vector platforms (ChAdOx and MVA, rooted in Oxford and NIH research) used to induce effector T cell responses against chronic viral infections and cancer, and the proprietary SNAP / SNAP-TI synthetic nanoparticle platform — programmable 20nm particles that co-deliver disease-relevant antigens with immunomodulators (mTOR inhibitor) to expand regulatory T cells and restore immune tolerance in autoimmune indications. Its clinical pipeline comprises VTP-1000 (Phase 1 celiac disease via SNAP-TI), VTP-300 (Phase 1b/2a chronic hepatitis B with positive HBV002 results), VTP-200 (Phase 1b/2 HPV-related cervical lesions), and VTP-850 (Phase 1/2 prostate cancer), with active clinical trial sites in the US and Europe listed on ClinicalTrials.gov.

The company is pre-revenue and discloses no product pricing or commercialization channels; the implied business model is to advance candidates through clinical development to regulatory approval, then commercialize through traditional pharmaceutical prescription-based distribution, supplemented by partnerships for selected programs (e.g., VTP-800/850 oncology assets). Revenue mechanics today consist solely of clinical-stage burn funded by equity and existing cash. As of year-end 2025, the company held $71.9M in cash and equivalents (down from $112.4M in 2024) with an expected runway through 2027; it reported a $66.4M FY2025 net loss and a Q1 2026 net loss narrowed to $5.5M from $19.6M as legacy program R&D was wound down. In September 2025, Barinthus entered a definitive all-stock merger agreement with Clywedog Therapeutics to create a combined entity (Clywedog Therapeutics Holdings / NASDAQ: CLYD) focused on metabolic and autoimmune diseases, expected to close mid-2026 with Barinthus shareholders retaining ~34%; four clinical milestones are anticipated within 18 months of close. Institutional investors collectively own 25.2% of the stock, and the company has financial backing from OrbiMed and Torrey Pines Investment LLC supporting the merger.

Name

Barinthus Biotherapeutics

Legal name

Barinthus Biotherapeutics plc

Website

https://barinthusbio.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Barinthus Biotherapeutics is a UK-based, NASDAQ-listed clinical-stage biopharmaceutical company developing antigen-specific immunotherapies using proprietary SNAP-TI synthetic nanoparticle and ChAdOx/MVA viral vector platforms to guide T cells for treating chronic infections, autoimmune diseases, and cancer.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (antigen-specific immunotherapy)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Antigen-specific immunotherapy
• Clinical-stage biopharmaceuticals
• Autoimmune disease therapy
• Cancer immunotherapy pipeline
• Chronic viral infection treatment

Headquarters

HQ city

Harwell

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Biopharmaceutical Product Development: As a clinical-stage biopharmaceutical company, Barinthus Biotherapeutics is pre-revenue. The company is developing antigen-specific immunotherapies across I&I indications and expects to generate revenue through the future sale of approved therapeutic products upon successful clinical development and regulatory authorization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies for autoimmune diseases, chronic viral infections, and cancer. Its pipeline comprises investigational drug candidates built on two proprietary platforms: SNAP-TI synthetic nanoparticles for tolerance induction and ChAdOx/MVA viral vectors for effector T cell responses. Lead programs include VTP-1000 for celiac disease (Phase 1), VTP-300 for chronic hepatitis B (Phase 1b/2a completed), VTP-200 for HPV-related cervical lesions (Phase 1b/2), and VTP-850 for prostate cancer (Phase 1/2).

Product overview

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing a portfolio of antigen-specific immunotherapies across immunology and inflammatory (I&I) indications. The company's pipeline centers on two proprietary technology platforms: SNAP-TI (Self-assembling Nanoparticles based on Amphiphilic Peptides) for tolerance induction in autoimmunity, and Viral Vector platforms (ChAdOx, MVA) for chronic infectious diseases and cancer. Key clinical programs include VTP-1000 (celiac disease), VTP-300 (hepatitis B), VTP-200 (HPV-related conditions), and VTP-850 (prostate cancer). The company is also pursuing partnership activities for its viral platform programs including VTP-800/850 in cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• VTP-1000 Antigen-specific immunotherapy utilizing the SNAP Tolerance Platform (SNAP-TI) co-delivering gluten antigens and an mTOR inhibitor to induce regulatory T cells for the treatment of celiac disease. Currently in Phase 1 clinical development with positive Single Ascending Dose tolerability and pharmacodynamic activity reported.
• VTP-300 Antigen-specific immunotherapy for chronic hepatitis B infection, the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) in the HBV002 Phase 1b/2a study.
• VTP-200 Immunotherapy for HPV-related cervical lesions, demonstrating favorable tolerability and immunogenicity profile in a Phase 1b/2 study in women with low-grade human papillomavirus-related cervical lesions.
• VTP-850 Phase 1/2 clinical-stage immunotherapy candidate for prostate cancer, evaluated in men with biochemical recurrence after definitive local therapy, leveraging the company's viral vector platform.

Quantifiable outcome

• Phase 1 AVALON trial of VTP-1000 for celiac disease showed positive tolerability and dose-dependent pharmacodynamic effects in the single ascending dose portion, with multiple ascending dose data expected in H2 2026.
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered supporting and core.

• ChemDivsupportingStrategic or Co-development Partner · 24 October 2025R&D services provider continuing to support Clywedog Therapeutics following the announced merger with Barinthus Biotherapeutics, indicating an ongoing research collaboration relationship.
• Clywedog TherapeuticscoreStrategic or Co-development Partner · 30 September 2025Definitive all-stock merger agreement combining Barinthus Bio with private biotech firm Clywedog Therapeutics to create a combined entity focused on metabolic and autoimmune diseases. Expected to close mid-2026. The combined company will be renamed 'Clywedog Therapeutics Holdings, Inc.' and trade on NASDAQ under ticker CLYD. Barinthus Bio shareholders will own approximately 34% and Clywedog stockholders approximately 66% of the combined entity on a fully diluted basis. Four clinical data milestones are expected within 18 months of closing.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• ImmusanT: Clinical-stage company developing Nexvax2, an antigen-specific peptide immunotherapy for celiac disease. Most direct competitor to Barinthus's VTP-1000 in celiac disease.
• Vir Biotechnology: Clinical-stage immunology company pursuing functional cure for chronic hepatitis B with antigen-specific immunotherapies. Most direct competitor to Barinthus's VTP-300 program in HBV.
• Arbutus Biopharma: Focused on developing a functional cure for chronic HBV using a combination strategy including RNAi and immunotherapies. Directly competes with Barinthus's VTP-300 in the HBV cure space.

Emerging players

• Adaptimmune Therapeutics: Clinical-stage T cell receptor (TCR) therapy company for solid tumors, including prostate cancer programs (ADP-A2M4CD8). Comparable in cancer immunotherapy space with overlapping prostate cancer indication.
• Anokion: Clinical-stage company developing antigen-specific tolerance immunotherapies for autoimmune diseases including celiac and multiple sclerosis. Direct overlap with Barinthus's SNAP-TI tolerance platform.
• Cour Pharmaceuticals: Clinical-stage company developing antigen-specific tolerance therapies for autoimmune diseases including celiac disease and type 1 diabetes. Overlaps with Barinthus's SNAP-TI autoimmune pipeline.

Broad incumbents

• Moderna: Major mRNA vaccine and immunotherapy company with broad pipeline including oncology and infectious disease candidates. Comparable as a clinical-stage immunotherapy developer with platform breadth exceeding Barinthus.
• BioNTech: mRNA immunotherapy leader with oncology and infectious disease pipeline. Comparable as a clinical-stage developer of antigen-specific immunotherapies, though at substantially larger scale and broader platform scope.
• Bavarian Nordic: Established vaccine and immunotherapy company with viral vector platform capabilities (MVA-BN) overlapping Barinthus's MVA-based immunotherapies, particularly in infectious disease and cancer.

Regional players

• Brii Biosciences: China-based infectious disease biotech with chronic HBV programs including siRNA and immunotherapy combinations. Competes in the HBV functional cure space though primarily in Asia-Pacific markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BarinthusBio
• LinkedInlinkedin.com/company/barinthusbiotherapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barinthus Biotherapeutics